Expert Review of Gastroenterology & Hepatology最新文献_第8页

Introducing the "Guideline Comparison" article type. 介绍“指南比较”文章类型。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-01-01 DOI: 10.1080/17474124.2025.2607006

James H Tabibian

引用次数: 0

Diagnostic and therapeutic strategies for biliary strictures: a comparison of ACG, ESGE, and ASGE guidelines. 胆道狭窄的诊断和治疗策略：ACG、ESGE和ASGE指南的比较

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-01-01 Epub Date: 2025-11-24 DOI: 10.1080/17474124.2025.2592076

Eyad Gadour, Stefano Francesco Crinò, Marco Spadaccini, Antonio Facciorusso

{"title":"Diagnostic and therapeutic strategies for biliary strictures: a comparison of ACG, ESGE, and ASGE guidelines.","authors":"Eyad Gadour, Stefano Francesco Crinò, Marco Spadaccini, Antonio Facciorusso","doi":"10.1080/17474124.2025.2592076","DOIUrl":"10.1080/17474124.2025.2592076","url":null,"abstract":"Introduction: The diagnostic management of biliary strictures remains a complex clinical challenge requiring evidence-based guidance. Multiple societies, including the European Society of Gastrointestinal Endoscopy (ESGE), American College of Gastroenterology (ACG), and American Society for Gastrointestinal Endoscopy (ASGE), have recently published guidelines with both consensus and divergence.Areas covered: A comparative analysis of the ESGE, ACG, and ASGE guidelines reveals shared principles, such as the role of MRI/MRCP in initial evaluation (moderate quality evidence), limited utility of tumor markers alone (low to very low quality evidence), and preference for metal stents in palliation (moderate quality evidence). Key differences arise in tissue acquisition for perihilar strictures, with ACG/ASGE discouraging EUS-guided sampling in surgical candidates (low-quality evidence), while ESGE conditionally supports its use in non-resectable cases candidates (low-quality evidence). The ASGE provides conditional recommendations on bilateral stenting for malignant hilar obstruction, not emphasized in other guidelines.Expert opinion: Although founded on similar evidence, guideline variations reflect differing risk tolerance and resource considerations. Clinicians must recognize these nuances to tailor management. Future research should clarify EUS seeding risk, evaluate cost-effectiveness, and inform harmonized guideline updates.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"11-16"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pediatric medical liver biopsy: indications, procedures, and histopathology. 儿科医学肝活检：指征、程序和组织病理学。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-01-01 Epub Date: 2026-01-18 DOI: 10.1080/17474124.2025.2607575

Consolato M Sergi

{"title":"The pediatric medical liver biopsy: indications, procedures, and histopathology.","authors":"Consolato M Sergi","doi":"10.1080/17474124.2025.2607575","DOIUrl":"10.1080/17474124.2025.2607575","url":null,"abstract":"Introduction: Investigative work in pediatric liver disease is rapidly growing. Despite noninvasive methods in place for several years, the medical liver biopsy is still a critical step for diagnosing and treating pediatric patients. We provide a narrative review focusing on indications, procedures, and histopathology of pediatric liver biopsy.Areas covered: We searched the PubMed, Scopus, and Cochrane databases for articles on pediatric liver biopsy, discussing the clinical implications of several procedures and their associated costs. We also complemented our search by digging into the gray literature (e.g., reports, abstracts, textbooks, and Google Scholar) for similar items. The search for articles was conducted between 1 January 2022, and 31 July 2025.Expert opinion: Pediatric liver biopsy is not limited to data gathered following formalin-fixation and paraffin-embedded liver tissue. It includes frozen tissue-based special stains, such as the oil red-O stain for lipids; a specimen devoted to ultrastructural analysis using a transmission electron microscope; and a flash-frozen tissue specimen used for future transcriptomics and genomic studies (e.g., single-nucleotide polymorphisms).","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"39-56"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary biliary cholangitis (PBC): evolving approaches and expert perspectives. 原发性胆管炎（PBC）：不断发展的方法和专家观点。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-01-01 Epub Date: 2025-12-19 DOI: 10.1080/17474124.2025.2601220

Pietro Invernizzi, Alessio Aghemo, Vincenza Calvaruso, Ana Lleo, Marco Marzioni, Fabio Piscaglia, Cristina Rigamonti, Umberto Vespasiani Gentilucci, Stefano Brillanti, Marco Carbone, Nora Cazzagon, Pietro Lampertico

{"title":"Primary biliary cholangitis (PBC): evolving approaches and expert perspectives.","authors":"Pietro Invernizzi, Alessio Aghemo, Vincenza Calvaruso, Ana Lleo, Marco Marzioni, Fabio Piscaglia, Cristina Rigamonti, Umberto Vespasiani Gentilucci, Stefano Brillanti, Marco Carbone, Nora Cazzagon, Pietro Lampertico","doi":"10.1080/17474124.2025.2601220","DOIUrl":"10.1080/17474124.2025.2601220","url":null,"abstract":"Introduction: Primary biliary cholangitis (PBC) is a rare, chronic autoimmune cholestatic liver disease causing progressive destruction of intrahepatic bile ducts. Predominantly affecting women aged 35 to 70, PBC may remain asymptomatic for years before symptoms such as pruritus, fatigue, or sicca symptoms manifest. If untreated, PBC can progress to cirrhosis, liver failure and need for transplantation, significantly impacting life expectancy.Areas covered: Ursodeoxycholic acid (UDCA) remains the only approved first-line therapy. The recent withdrawal of obeticholic acid (OCA) from the European market, the only available second-line agent since 2016, highlighting the need for alternative options. The recent European Medicine Agency (EMA) approval of new peroxisome proliferator-activated receptor (PPAR) agonists is promising for patients with suboptimal response to UDCA. A literature review was conducted to map the patient journey and examine current treatments.Expert opinion: A panel of Italian expert hepatologists was involved to explore unmet needs along the patient journey and define clinical priorities. Focus areas included response monitoring, treatment evaluation timing, symptoms management - particularly pruritus and fatigue - and care of comorbid and high-risk patients. Many patients live with indolent disease, but some may require a more structured pathway, where emerging treatments can be an important turning point.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"17-28"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145762721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endoscopic follow-up in patients with first-degree relatives for gastric cancer: a real-world observational study. 胃癌一级亲属患者的内镜随访：一项真实世界的观察性研究。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-01-01 Epub Date: 2025-12-23 DOI: 10.1080/17474124.2025.2607007

Irene Ligato, Emanuele Dilaghi, Giulio Cozza, Emanuela Pilozzi, Edith Lahner, Francesco Panzuto, Bruno Annibale, Gianluca Esposito

{"title":"Endoscopic follow-up in patients with first-degree relatives for gastric cancer: a real-world observational study.","authors":"Irene Ligato, Emanuele Dilaghi, Giulio Cozza, Emanuela Pilozzi, Edith Lahner, Francesco Panzuto, Bruno Annibale, Gianluca Esposito","doi":"10.1080/17474124.2025.2607007","DOIUrl":"10.1080/17474124.2025.2607007","url":null,"abstract":"Background: First-degree family history of gastric cancer is a risk factor for gastric cancer and precancerous conditions, but only a few studies exist regarding the endoscopic follow-up of these patients. This study investigates endoscopic and histological findings over a 15-year period in patients with first-degree relatives of gastric cancer intestinal type who underwent follow-up upper gastrointestinal endoscopies.Research design and methods: We conducted a retrospective real-world observational study involving patients who underwent at least two upper gastrointestinal endoscopies between 2008 and 2023 at Sant'Andrea Hospital, Rome. The study analyzed histological findings, dividing participants into four subgroups based on their baseline conditions [H. pylori infection, gastric atrophy, intestinal metaplasia, dysplasia].Results: One hundred and six patients were included, only 13% were indicated for follow-up endoscopy according to the MAPS guidelines. An additional 13% of patients developed precancerous conditions, most of whom were H. pylori positive at the index examination, with an odds ratio risk of 6.778 (p = 0.004).Conclusions: Performing routinely virtual chromoendoscopy during the index endoscopy in these patients could improve the detection of precancerous conditions. Special attention should be given to H. pylori-positive patients due to their increased risk of developing precancerous conditions, for whom follow-up endoscopies may be beneficial.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"63-69"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From liver to gut: the hidden gastrointestinal impact of pediatric metabolic dysfunction-associated steatotic liver disease. 从肝脏到肠道：儿童代谢功能障碍相关脂肪变性肝病的隐性胃肠道影响

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-12-01 Epub Date: 2025-12-05 DOI: 10.1080/17474124.2025.2600386

Gianmario Forcina, Vittoria Frattolillo, Maria De Cesare, Assunta Floriano, Rosamaria Palma, Federica Casamassima, Mario Bartiromo, Pierluigi Marzuillo, Emanuele Miraglia Del Giudice, Anna Di Sessa

{"title":"From liver to gut: the hidden gastrointestinal impact of pediatric metabolic dysfunction-associated steatotic liver disease.","authors":"Gianmario Forcina, Vittoria Frattolillo, Maria De Cesare, Assunta Floriano, Rosamaria Palma, Federica Casamassima, Mario Bartiromo, Pierluigi Marzuillo, Emanuele Miraglia Del Giudice, Anna Di Sessa","doi":"10.1080/17474124.2025.2600386","DOIUrl":"10.1080/17474124.2025.2600386","url":null,"abstract":"Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disorder in children and is increasingly recognized as a multisystem condition. Among its extrahepatic manifestations, gastrointestinal (GI) comorbidities significantly influence disease progression and long-term outcomes. A deeper understanding of the liver - gut pathophysiological interplay is essential for developing integrated, multidisciplinary management strategies.Areas covered: This narrative review summarizes current evidence on hepatic and GI comorbidities in pediatric MASLD. A comprehensive literature search was conducted across PubMed, EMBASE, and Google Scholar to identify relevant studies published to date. Beyond disease progression, the review highlights the wide spectrum of GI comorbidities, potential malignancy risks, and emerging pathophysiological insights that may inform the development of targeted therapeutic strategies.Expert opinion: MASLD is a significant early-life risk factor for various GI comorbidities, highlighting the need for thorough GI assessment in pediatric MASLD management. Early detection, prevention, and comprehensive management are essential to reduce long-term complications and slow disease progression. Developing pediatric-specific guidelines and validated noninvasive biomarkers is crucial to enable standardized screening, risk stratification, and monitoring. Continued research - especially incorporating omics technologies - is vital for improving risk prediction, enabling earlier diagnosis, and advancing personalized therapies, ultimately enhancing outcomes and reducing disease burden.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1329-1343"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment optimization of subcutaneous infliximab in patients with inflammatory bowel disease. 炎症性肠病患者皮下英夫利昔单抗的治疗优化

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-12-01 Epub Date: 2025-11-19 DOI: 10.1080/17474124.2025.2591151

Ajay Gade, Alessandra Saraga, Tina Deyhim, Grace Geeganage, Adam S Cheifetz, Konstantinos Papamichael

{"title":"Treatment optimization of subcutaneous infliximab in patients with inflammatory bowel disease.","authors":"Ajay Gade, Alessandra Saraga, Tina Deyhim, Grace Geeganage, Adam S Cheifetz, Konstantinos Papamichael","doi":"10.1080/17474124.2025.2591151","DOIUrl":"10.1080/17474124.2025.2591151","url":null,"abstract":"Introduction: Subcutaneous infliximab (SC-IFX) is an efficacious medication for inflammatory bowel disease (IBD). However, there is limited information about treatment optimization following loss of response (LOR), the role of therapeutic drug monitoring (TDM), and combination therapy with an immunomodulator (IMM) and efficacy of SC-IFX in perianal fistulizing Crohn's disease (CD).Areas covered: This narrative review will provide an overview of the efficacy of SC-IFX in IBD including perianal fistulising CD, the effectiveness of dose escalation after LOR, and the role of TDM and IMM use. A literature search was performed using PubMed and reviewed references from applicable manuscripts and abstracts from major gastrointestinal medical congresses between January 2021 and 20 May 2025.Expert opinion: Current data suggest that SC-IFX is effective in the treatment of IBD. Moreover, cumulative data suggest that dose escalation is effective in recapturing response in patients with LOR, and that higher drug concentrations are associated with better outcomes. However, there are still major gaps in understanding the role of drug clearance, immunogenicity, and the role of TDM for optimizing SC-IFX. Moreover, the impact of body mass index and concomitant IMM therapy on clinical outcomes as well as the efficiency of SC-IFX in more complicated IBD phenotypes remains to be elucidated.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1257-1266"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145523243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of pediatric abdominal pain: what is the evidence? 小儿腹痛的治疗：证据是什么？

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-12-01 Epub Date: 2025-11-23 DOI: 10.1080/17474124.2025.2592089

Miguel Saps, Samantha Arrizabalo

{"title":"Treatment of pediatric abdominal pain: what is the evidence?","authors":"Miguel Saps, Samantha Arrizabalo","doi":"10.1080/17474124.2025.2592089","DOIUrl":"10.1080/17474124.2025.2592089","url":null,"abstract":"Introduction: Abdominal pain disorders (APDs), including irritable bowel syndrome (IBS) and functional abdominal pain - not otherwise specified (FAP), are highly prevalent in children and significantly impact quality of life. This review highlights advances addressing the need for standardized, evidence-based management in this population.Areas covered: This review summarizes the first evidence-based treatment guidelines for pediatric IBS and FAP, developed jointly by the European and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. The recommendations were based on a systematic review of randomized controlled trials identified through searches in PubMed, Embase, and Cochrane CENTRAL databases [1984 - June 2023]. Strong recommendations were issued for hypnotherapy and cognitive behavioral therapy, with conditional suggestions for probiotics, symbiotics, peppermint oil, soluble fiber, and selected pharmacologic agents. To complement this work, we performed an updated literature search covering studies published after June 2023.Expert opinion: These guidelines represent a critical advancement in standardizing the management of pediatric APDs by showing how each recommendation is supported by the available evidence. They offer practical guidance for clinicians navigating a complex and often fragmented treatment landscape. Future efforts should prioritize addressing current knowledge gaps and evaluating the impact of these recommendations on clinical outcomes.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1267-1271"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145534280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent developments in biomarker guided therapy for Crohn's disease. 生物标志物引导治疗克罗恩病的最新进展。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-12-01 Epub Date: 2025-12-02 DOI: 10.1080/17474124.2025.2590179

André Bargas, Joana Torres, Bram Verstockt

{"title":"Recent developments in biomarker guided therapy for Crohn's disease.","authors":"André Bargas, Joana Torres, Bram Verstockt","doi":"10.1080/17474124.2025.2590179","DOIUrl":"10.1080/17474124.2025.2590179","url":null,"abstract":"Introduction: Crohn's disease (CD) is a chronic inflammatory condition with a highly variable course and unpredictable treatment response. As the therapeutic landscape expands, there is a growing need for biomarkers that can support earlier diagnosis, risk-stratification, treatment selection, and that can inform monitoring or discontinuation strategies.Areas covered: This review explores the current state of biomarker development and application in CD across multiple disease stages - from prediction and prognosis to therapeutic response and monitoring. It critically appraises the evidence for serologic, genetic, transcriptomic, proteomic, and epigenetic markers, and highlights their potential roles, limitations, and barriers to clinical implementation.Expert opinion: Despite major scientific advances, precision medicine in CD remains largely unrealized, hindered by a lack of validated and deployable biomarkers. The field must urgently pivot from discovery to implementation, embedding biomarkers into clinical trial design, validating multi-omic signatures across diverse subtypes, and overcoming real-world barriers of cost, standardization, and regulation. We can no longer accept navigating CD management blindfolded. Precision medicine should no longer be a distant aspiration. It should be the standard we hold ourselves to. The ceiling will only break when we stop accepting it.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1241-1255"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145512333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Measuring gut microbiome as a colorectal cancer screening tool: potential and challenges. 测量肠道微生物组作为结直肠癌筛查工具：潜力和挑战。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-12-01 Epub Date: 2025-11-28 DOI: 10.1080/17474124.2025.2592078

Andrea Severino, Stefano Andrea Marchitto, Piergiorgio Bisegna, Serena Porcari, Debora Rondinella, Tommaso Schepis, Federico Barbaro, Silvia Pecere, Marcello Maida, Cristiano Spada, Antonio Gasbarrini, Giovanni Cammarota, Antonio Facciorusso, Gianluca Ianiro

{"title":"Measuring gut microbiome as a colorectal cancer screening tool: potential and challenges.","authors":"Andrea Severino, Stefano Andrea Marchitto, Piergiorgio Bisegna, Serena Porcari, Debora Rondinella, Tommaso Schepis, Federico Barbaro, Silvia Pecere, Marcello Maida, Cristiano Spada, Antonio Gasbarrini, Giovanni Cammarota, Antonio Facciorusso, Gianluca Ianiro","doi":"10.1080/17474124.2025.2592078","DOIUrl":"10.1080/17474124.2025.2592078","url":null,"abstract":"Introduction: Colorectal cancer (CRC) represents a global public health challenge, ranking as the third most prevalent cancer globally. Population-based screening programs for average-risk populations have proven effective in reducing incidence and mortality of CRC through early detection of cancer. The fecal immunochemical test (FIT), the standard diagnostic method in many nations, still falls short in diagnostic effectiveness, resulting in undetected adenomas and, more significantly, unnecessary colonoscopies.Areas covered: One of the primary research focuses in the field of CRC is the discovery of new, noninvasive biomarkers. Recent studies, including metagenomic meta-analyses, have discovered common microbial signatures able to reproducibly discriminate between patients with CRC and healthy controls. Based on this evidence, international guidelines have recently recommended the use of microbiome-based biomarkers for CRC screening in clinical settings, although such studies have yet to be conducted.Expert opinion: This field of research needs considerable multidisciplinary efforts, including large and geographically different meta-cohorts, and the application of state-of-the-art computational approaches, to identify reproducible signatures able to predict early lesions. Such diagnostic tool would revolutionize CRC screening. More widely, it would provide a mind-set shift in the clinical and scientific community promoting the exploitation of diagnostic and therapeutic microbiome tools in clinical practice.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1285-1298"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145548956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0